Helping Desperately Ill Patients Get Access to Experimental Medicines
Clinical Research Pathways works with the Food and Drug Administration’s (FDA’s) expanded access process.
Our goal is to enable desperately ill patients to access experimental treatments—without causing undue harm to them or jeopardizing drug development for future patients.
We help simplify the approval process.
We do that by providing educational materials and training to institutional review boards (IRBs) and physicians.
As a resource on expanded access, we help patients, physicians, and IRBs use the approval process, understand new “right-to-try” legislation, and take advantage of FDA options that create access for larger groups of patients. Click to view additional resources.